GlobeNewsWire
21 Jul 2026, 17:51 UTC · 2h ago
Immix Biopharma Investigated by the Portnoy Law Firm
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
21 Jul 2026, 17:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
An Immix Biopharma executive operating under the alias 'Richard Graydon' was allegedly Ronald Fischer, a top fugitive wanted in Rhode Island. — The employment of a high-level fugitive suggests a severe failure in corporate governance and due diligence, damaging investor trust.
-0.60The Portnoy Law Firm has initiated an investigation into Immix Biopharma for possible securities fraud and potential class action litigation. — Legal investigations and potential class action lawsuits create financial uncertainty and overhead costs for the company.
-0.50Immix Biopharma's share price dropped approximately 10.83% following reports of the executive's identity. — This represents an immediate negative market reaction and a loss of market capitalization.
-0.30Continue reading
6 related stories
Search tags
Immix Biopharma terminated the officer on July 17, 2026, and claims no material financial or operational impact is expected. — Management's attempt to contain the damage and isolate the incident acts as a slight stabilizer against further panic.
+0.20Which stocks this story touches
The company is under investigation for possible securities fraud following the discovery that an executive was a fugitive, resulting in a 10.83% share price drop.
The company is being targeted for a class action lawsuit by the Portnoy Law Firm.
The company is being targeted for a class action lawsuit by the Portnoy Law Firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
